August 2016

HelixBind awarded a $2.4M Direct-to-Phase II SBIR from the National Institutes of Health (NIH) to automate its sample-to-answer test for discriminating among bacterial pathogens

Ibriz Moonim
April 2016

HelixBind files patent application for automated device-based consumable used for identifying pathogenic microorganisms directly from whole-blood at ultra-low concentrations.

Ibriz Moonim
March 2016

HelixBind published its work, completed in collaboration with Tufts Medical Center and Sloan Memorial Kettering Cancer Center demonstrating successful implementation of its novel sample-to-answer Core Pathogen Identification (C/PID) platform for identifying bloodstream infections directly from patient specimens in under 2.5 hours. For more information:

http://mbio.asm.org/content//7/2/e00345-16.full 

Ibriz Moonim
September 2015

HelixBind awarded a $300k Phase I SBIR from the National Institutes of Health (NIH) to develop a sample-to-answer test capable of classifying different infections prevalent in neonatal sepsis

Ibriz Moonim
August 2015

Based on its successful Phase I results, HelixBind awarded a follow on Phase II SBIR in the amount of $1.5M from the National Institutes of Health (NIH) to automated its sample-to-answer test for discriminating among fungal pathogens

Ibriz Moonim
September 2014

HelixBind files patent application for methods, sequences, and reagents used for identifying pathogenic microorganisms directly from whole-blood at ultra-low concentrations.

Ibriz Moonim
August 2014

HelixBind awarded a $300k Phase I SBIR from the National Institutes of Health (NIH) to develop a sample-to-answer artificial nucleic acid probe based technology for discriminating among fungal pathogens common in bloodstream infections.

Ibriz Moonim
January 2014

Based on its successful Phase I results, HelixBind awarded a follow on $60k Phase IB for extending it artificial nucleic acid probe based technology for discriminating among Staphylococci

Ibriz Moonim
August 2013

HelixBind awarded a $178k Phase I SBIR from National Institutes of Health (NIH) to develop a novel dipstick test for discriminating among Helicobacter species for use in the research setting.

Ibriz Moonim
June 2013

HelixBind awarded a $150k Phase I SBIR from the National Science Foundation (NSF) to develop an artificial nucleic acid probe based technology for discriminating among Enterococci.

Ibriz Moonim
March 2013

HelixBind files patent application for sequences used for identifying pathogenic microorganisms utilizing a unique artificial nucleic acid probe

Ibriz Moonim